TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT02448173: A Multicenter Study of Active Specific Immunotherapy With OncoVax® in Patients With Stage II Colon Cancer

Sponsor: Vaccinogen Inc · Phase: PHASE3 · Area: ONCOLOGY · Target Enrollment: 550 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$20,993,280

Rescue Site Savings

+$13,842,444

Unlock Full NCT02448173 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT02448173 Rescue Dossier →